Previous Close | 18.53 |
Open | 19.07 |
Bid | 17.77 x 100 |
Ask | 17.88 x 200 |
Day's Range | 17.43 - 19.24 |
52 Week Range | 10.38 - 20.67 |
Volume | |
Avg. Volume | 132,255 |
Market Cap | 937.552M |
Beta (5Y Monthly) | 1.12 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.62 |
Earnings Date | May 02, 2024 - May 06, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 24.60 |
Recent Financial Highlights Indicate Strong Cash Position and Advancements in Clinical Studies
Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the fourth quarter and full year ended December 31, 2023 and highlighted recent corporate progress.
Tyra Biosciences Inc (NASDAQ:TYRA), a company focused on developing precision medicine for patients with cancer, has reported an insider sell according to a recent SEC filing.